The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus
Open accessAbstract
Methicillin-resistant Staphylococcus aureus (MRSA) infections present a serious challenge because of the emergence of resistance to numerous conventional antibiotics. Due to their unique mode of action, antimicrobial peptides are novel alternatives to traditional antibiotics for tackling the issue of bacterial multidrug resistance. Herein, we investigated the antibacterial activity of two short novel peptides (WR12, a 12 residue peptide composed exclusively of arginine and tryptophan, and D-IK8, an eight residue β-sheet peptide) against multidrug resistant staphylococci. In vitro, both peptides exhibited good antibacterial activity against MRSA, vancomycin-resistant S. aureus, linezolid-resistant S. aureus, and methicillin-resistant S. epidermidis. WR12 and D-IK8 were able to eradicate persisters, MRSA in stationary growth phase, and showed significant clearance of intracellular MRSA in comparison to both vancomycin and linezolid. In vivo, topical WR12 and D-IK8 significantly reduced both the bacterial load and the levels of the pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in MRSA-infected skin lesions. Moreover, both peptides disrupted established in vitro biofilms of S. aureus and S. epidermidis significantly more so than traditional antimicrobials tested. Taken together, these results support the potential of WR12 and D-IK8 to be used as a topical antimicrobial agent for the treatment of staphylococcal skin infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Mechanisms of biofilm resistance to antimicrobial agents
Mah, T.-F. C., & O'Toole, G. A. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(00)01913-2 · Cited by 3,921
Inflammation in Wound Repair: Molecular and Cellular Mechanisms
Eming, S. A., Krieg, T., & Davidson, J. M. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700701 · Cited by 2,429
Persister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Innate antimicrobial peptide protects the skin from invasive bacterial infection
Nizet, V., Ohtake, T., Lauth, X., Trowbridge, J., Rudisill, J., Dorschner, R. A., Pestonjamasp, V., Piraino, J., Huttner, K., & Gallo, R. L. (2001) · Nature · doi:10.1038/35106587 · Cited by 1,198
Persister cells and tolerance to antimicrobials
Keren, I., Kaldalu, N., Spoering, A., Wang, Y., & Lewis, K. (2004) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(03)00856-5 · Cited by 1,098
Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action
Chan, D. I., Prenner, E. J., & Vogel, H. J. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.04.006 · Cited by 1,039
Staphylococcus aureus biofilms: Properties, regulation, and roles in human disease
Archer, N. K., Mazaitis, M. J., Costerton, J. W., Leid, J. G., Powers, M. E., & Shirtliff, M. E. (2011) · Virulence · doi:10.4161/viru.2.5.17724 · Cited by 1,018
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils
Turner, J., Cho, Y., Dinh, N.-N., Waring, A. J., & Lehrer, R. I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2206 · Cited by 798
King, M. D., Humphrey, B. J., Wang, Y. F., Kourbatova, E. V., Ray, S. M., & Blumberg, H. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00005 · Cited by 776
Activated ClpP kills persisters and eradicates a chronic biofilm infection
Conlon, B. P., Nakayasu, E. S., Fleck, L. E., LaFleur, M. D., Isabella, V. M., Coleman, K., Leonard, S. N., Smith, R. D., Adkins, J. N., & Lewis, K. (2013) · Nature · doi:10.1038/nature12790 · Cited by 672
Antimicrobial peptides and the skin immune defense system
Schauber, J., & Gallo, R. L. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.03.027 · Cited by 477
How do bacteria resist human antimicrobial peptides?
Peschel, A. (2002) · Trends in Microbiology · doi:10.1016/s0966-842x(02)02333-8 · Cited by 465
Immunity against Staphylococcus aureus cutaneous infections
Miller, L. S., & Cho, J. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3010 · Cited by 434
Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window
Wolcott, R. D., Rumbaugh, K. P., James, G., Schultz, G., Phillips, P., Yang, Q., Watters, C., Stewart, P. S., & Dowd, S. E. (2010) · Journal of Wound Care · doi:10.12968/jowc.2010.19.8.77709 · Cited by 423
Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms
Singh, R., Ray, P., Das, A., & Sharma, M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq257 · Cited by 422
In Vitro Antibacterial Properties of Pexiganan, an Analog of Magainin
Ge, Y., MacDonald, D. L., Holroyd, K. J., Thornsberry, C., Wexler, H., & Zasloff, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.782 · Cited by 359
Lipsky, B. A., Holroyd, K. J., & Zasloff, M. (2008) · Clinical Infectious Diseases · doi:10.1086/593185 · Cited by 324
Nosocomial Septicemia Due to Multiply Antibiotic-Resistant Staphylococcus epidermidis
CHRISTENSEN, G. D., BISNO, A. L., PARISI, J. T., McLAUGHLIN, B., HESTER, M. G., & LUTHER, R. W. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-1-1 · Cited by 308
Chronic wounds and the medical biofilm paradigm
Wolcott, R. D., Rhoads, D. D., Bennett, M. E., Wolcott, B. M., Gogokhia, L., Costerton, J. W., & Dowd, S. E. (2010) · Journal of Wound Care · doi:10.12968/jowc.2010.19.2.46966 · Cited by 306
Stryjewski, M. E., & Chambers, H. F. (2008) · Clinical Infectious Diseases · doi:10.1086/533593 · Cited by 268
Penetration of vancomycin into human lung tissue
Cruciani, M., Gatti, G., Lazzarini, L., Furlan, G., Broccali, G., Malena, M., Franchini, C., & Concia, E. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.5.865 · Cited by 264
Dean, S. N., Bishop, B. M., & van Hoek, M. L. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-114 · Cited by 219
Thangamani, S., Mohammad, H., Abushahba, M. F. N., Sobreira, T. J. P., Hedrick, V. E., Paul, L. N., & Seleem, M. N. (2016) · Scientific Reports · doi:10.1038/srep22571 · Cited by 211
Self-citationvon Eiff, C., Becker, K., Metze, D., Lubritz, G., Hockmann, J., Schwarz, T., & Peters, G. (2001) · Clinical Infectious Diseases · doi:10.1086/320519 · Cited by 190
Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections
Kollef, M. H. (2007) · Clinical Infectious Diseases · doi:10.1086/519470 · Cited by 178
Deslouches, B., Steckbeck, J. D., Craigo, J. K., Doi, Y., Mietzner, T. A., & Montelaro, R. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02218-12 · Cited by 173
Deslouches, B., Islam, K., Craigo, J. K., Paranjape, S. M., Montelaro, R. C., & Mietzner, T. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3208-3216.2005 · Cited by 159
Ellington, J. K., Harris, M. B., Hudson, M., et al. (2005) · Journal of Orthopaedic Research® · doi:10.1002/jor.20003 · Cited by 156
Staphylococcus aureus Persisters Tolerant to Bactericidal Antibiotics
Lechner, S., Lewis, K., & Bertram, R. (2012) · Microbial Physiology · doi:10.1159/000342449 · Cited by 155
Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections
Thangamani, S., Younis, W., & Seleem, M. N. (2015) · Scientific Reports · doi:10.1038/srep11596 · Cited by 151
Self-citationCellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives.
Françoise Van Bambeke, A., Barcia-Macay, M., Lemaire, S., & Tulkens, P. M. (2006) · PubMed · Cited by 138
Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent
Thangamani, S., Mohammad, H. T., Abushahba, M. F. N., Hamed, M. I., Sobreira, T. J. P., Hedrick, V., Paul, L. N., & Seleem, M. N. (2015) · Scientific Reports · doi:10.1038/srep16407 · Cited by 138
Self-citationNguyen, H. M., & Graber, C. J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp377 · Cited by 122
Ong, Z. Y., Cheng, J., Huang, Y., Xu, K., Ji, Z., Fan, W., & Yang, Y. Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.053 · Cited by 119
Boosting Salt Resistance of Short Antimicrobial Peptides
Chu, H., Yu, H., Yip, B., Chih, Y., Liang, C.-W., Cheng, H.-T., & Cheng, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00252-13 · Cited by 114
Targeting Methicillin-Resistant Staphylococcus aureus with Short Salt-Resistant Synthetic Peptides
Mohamed, M. F., Hamed, M. I., Panitch, A., & Seleem, M. N. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02578-14 · Cited by 111
Self-citationReport of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States
Limbago, B. M., Kallen, A. J., Zhu, W., Eggers, P., McDougal, L. K., & Albrecht, V. S. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02187-13 · Cited by 101
Repurposing celecoxib as a topical antimicrobial agent
Thangamani, S., Younis, W., & Seleem, M. N. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00750 · Cited by 95
Self-citationRepurposing auranofin for the treatment of cutaneous staphylococcal infections
Thangamani, S., Mohammad, H. T., Abushahba, M. F. N., Sobreira, T. J. P., & Seleem, M. N. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.12.016 · Cited by 91
Self-citationMohammad, H. T., Mayhoub, A. S., Cushman, M., & Seleem, M. N. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.142 · Cited by 90
Self-citationInvestigational drugs to treat methicillin-resistantStaphylococcus aureus
Vuong, C., Yeh, A. J., Cheung, G. Y. C., & Otto, M. J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1109077 · Cited by 81
Ouhara, K., Komatsuzawa, H., Kawai, T., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn106 · Cited by 75
Sensitization of gram‐negative bacteria by targeting the membrane potential
Goldberg, K., Sarig, H., Zaknoon, F., Epand, R. F., Epand, R. M., & Mor, A. (2013) · The FASEB Journal · doi:10.1096/fj.13-227942 · Cited by 69
Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Mohammad, H. T., Thangamani, S., & Seleem, M. N. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150310102702 · Cited by 69
Self-citationKresken, M., Häfner, D., Schmitz, F., & Wichelhaus, T. A. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.11.007 · Cited by 68
Marks, L. R., Clementi, E. A., & Håkansson, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043514 · Cited by 62
Marks, L. R., Clementi, E. A., & Håkansson, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063158 · Cited by 58
Marcellini, L., Borro, M., Gentile, G., et al. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07257.x · Cited by 51
Antibiotics as Anti-Inflammatory and Immunomodulatory Agents
Rubin, B. K., & Tamaoki, J. (2005) · Birkhäuser-Verlag eBooks · doi:10.1007/b137084 · Cited by 50
Enhancement of antibiotic activity by sub-lethal concentrations of enterocin CRL35
Minahk, C. J. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh079 · Cited by 48
Mohammad, H. T., Cushman, M., & Seleem, M. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142321 · Cited by 47
Self-citationSeleem, M. N., & Mohamed, M. F. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s72129 · Cited by 43
Self-citationThe advance of bacterididal drugs in the treatment of infection
Alder, J. D., & Eisenstein, B. I. (2004) · Current Infectious Disease Reports · doi:10.1007/s11908-004-0042-1 · Cited by 39
Local Inflammation Exacerbates the Severity of Staphylococcus aureus Skin Infection
Montgomery, C. P., Daniels, M. D., Zhao, F., Spellberg, B. J., Chong, A. S., & Daum, R. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069508 · Cited by 36
Research works printed but not linked: 2
- Flamm, R. K. et al. In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. Antimicrob. Agents Chemother. 59, 1751–1754, 10.1128/AAC.04773-14 (2015). · doi:10.1128/aac.04773-14
- Mohamed, M. F., Hammac, G. K., Guptill, L. & Seleem, M. N. Antibacterial activity of novel cationic peptides against clinical isolates of multi-drug resistant Staphylococcus pseudintermedius from infected dogs. PloS one 9, e116259, 10.1371/journal.pone.0116259 (2014). · doi:10.1371/journal.pone.0116259
Cited by
Antimicrobial peptides for combating drug-resistant bacterial infections
Xuan, J., Feng, W., Wang, J., Wang, R., Zhang, B., Bo, L., Chen, Z.-S., Yang, H., & Sun, L. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100954 · Cited by 665
Mofazzal Jahromi, M. A., Sahandi Zangabad, P., Moosavi Basri, S. M., Sahandi Zangabad, K., Ghamarypour, A., Aref, A. R., Karimi, M., & Hamblin, M. R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.001 · Cited by 551
Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds
Pfalzgraff, A., Brandenburg, K., & Weindl, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00281 · Cited by 481
Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)
Dijksteel, G. S., Ulrich, M. M. W., Middelkoop, E., & Boekema, B. K. H. L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.616979 · Cited by 428
Antimicrobial peptides under clinical investigation
Koo, H. B., & Seo, J. (2019) · Peptide Science · doi:10.1002/pep2.24122 · Cited by 376
Metadata
- Authors
- Mohamed, M. F., Abdelkhalek, A., & Seleem, M. N.
- Venue
- Scientific Reports
- Published
- 2016-07-11
- Volume
- 6
- Issue
- 1
- Pages
- 29707-29707
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2474255949
- Cited by
- 275
- References
- 58
- FWCI
- 23.48
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.